These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7769051)

  • 21. The effects of gonadotrophin-releasing hormone agonist on follicular development in patients with polycystic ovary syndrome in an in-vitro fertilization and embryo transfer programme.
    Gersak K; Meden-Vrtovec H; Tomazevic T
    Hum Reprod; 1994 Sep; 9(9):1596-9. PubMed ID: 7836506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.
    Smith EM; Anthony FW; Gadd SC; Masson GM
    BMJ; 1989 Jun; 298(6686):1483-6. PubMed ID: 2503080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histological evaluation of endometrium on the day of oocyte retrieval after gonadotrophin-releasing hormone agonist-follicle stimulating hormone ovulation induction for in-vitro fertilization.
    Lass A; Peat D; Avery S; Brinsden P
    Hum Reprod; 1998 Nov; 13(11):3203-5. PubMed ID: 9853881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimum dose and mode of administration of luteinizing hormone releasing hormone analogue in in-vitro fertilization: a comparison of three regimens.
    Wren M; Tan SL; Waterstone J; Parsons J
    Hum Reprod; 1991 Nov; 6(10):1370-2. PubMed ID: 1770128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary suppression in ultrasound-monitored frozen embryo replacement cycles. A randomised study.
    El-Toukhy T; Taylor A; Khalaf Y; Al-Darazi K; Rowell P; Seed P; Braude P
    Hum Reprod; 2004 Apr; 19(4):874-9. PubMed ID: 15016780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles.
    Wu Z; Li R; Ma Y; Deng B; Zhang X; Meng Y; Chen X; Liu P; Qiao J
    Reprod Biomed Online; 2012 May; 24(5):511-20. PubMed ID: 22417667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of two gonadotropin-releasing hormone (GnRH) analogues (leuprolide and buserelin) in short and long protocols for assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Pados G; Mantalenakis S
    J Assist Reprod Genet; 1994 Feb; 11(2):85-91. PubMed ID: 7819707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between nafarelin acetate and D-Trp6-LHRH for temporary pituitary suppression in in vitro fertilization (IVF) patients: a prospective crossover study.
    Tanos V; Friedler S; Shushan A; Strauss N; Hetsroni I; Lewin A
    J Assist Reprod Genet; 1995 Nov; 12(10):715-9. PubMed ID: 8624429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: a comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact.
    Oyesanya OA; Teo SK; Quah E; Abdurazak N; Lee FY; Cheng WC
    Hum Reprod; 1995 May; 10(5):1042-4. PubMed ID: 7657737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
    Claman P; Domingo M; Leader A
    Hum Reprod; 1992 Apr; 7(4):487-9. PubMed ID: 1522190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens.
    Devroey P; Mannaerts B; Smitz J; Coelingh Bennink H; Van Steirteghem A
    Hum Reprod; 1994 Jun; 9(6):1064-9. PubMed ID: 7962377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and HMG.
    Smitz J; Devroey P; Braeckmans P; Camus M; Khan I; Staessen C; Van Waesberghe L; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1987 May; 2(4):309-14. PubMed ID: 3114314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).
    Monroe SE; Blumenfeld Z; Andreyko JL; Schriock E; Henzl MR; Jaffe RB
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1334-41. PubMed ID: 2946710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose.
    Buckett WM; Bentick B; Shaw RW
    Hum Reprod; 1998 Apr; 13(4):811-4. PubMed ID: 9619529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gonadotropin stimulation following GnRH-a priming for poor responders in in vitro fertilization-embryo transfer programs.
    Pinkas H; Orvieto R; Avrech OM; Rufas O; Ferber A; Ben-Rafael Z; Fisch B
    Gynecol Endocrinol; 2000 Feb; 14(1):11-4. PubMed ID: 10813101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation.
    Smitz J; Bourgain C; Van Waesberghe L; Camus M; Devroey P; Van Steirteghem AC
    Hum Reprod; 1993 Jan; 8(1):40-5. PubMed ID: 8458924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-ovulatory progesterone growth rate in patients treated with gonadotrophin-releasing hormone agonist and outcome of in-vitro fertilization.
    Gonen Y; Dirnfeld M; Goldman S; Koifman M; Abramovici H
    Hum Reprod; 1993 Sep; 8(9):1376-9. PubMed ID: 8253921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.